Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT)
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether treatment with etoposide, doxorubicin,
cisplatin and mitotane (EDP/M) prolongs survival as compared to streptozotocin and mitotane
(Sz/M) in patients with advanced adrenocortical carcinoma (ACC) whose disease is not amenable
to complete surgical resection.
Phase:
Phase 3
Details
Lead Sponsor:
Collaborative Group for Adrenocortical Carcinoma Treatment
Collaborators:
German Federal Ministry of Education and Research National Cancer Institute (NCI)